Skip to main content
Equibles

ADAR1 Capital Management, LLC

Position in REPL — Replimune Group, Inc.

CIK 1940272 AUSTIN, TX
Back to REPL Full portfolio

Position in REPL

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$7,259,528
-$4,850,322 QoQ
Shares Held
655,784
-58.6% QoQ
Ownership
0.696%
of shares outstanding
% of Portfolio
0.35%
of 13F equity value
Holder Rank
#32
of 199 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in REPL Over Time

Shares Held

Position Value (USD)

Derivatives in REPL

reported options exposure · as of Mar 31, 2026
CallValue
$765,000
CallShares
100,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ADAR1 Capital Management, LLC holds $1,760,528,411 across 192 Biotechnology names. REPL ranks #59 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ABVX
Abivax S.A.
 1,804,703 $240,494,721
2 PTGX
Protagonist Therapeutics, Inc
 960,863 $117,782,586
3 ROIV
Roivant Sciences Ltd.
 3,157,008 $111,726,513
4 IMVT
Immunovant, Inc.
 2,330,716 $89,802,487
5 ZLAB
Zai Lab Ltd
 3,369,034 $64,011,646
6 AGIO
Agios Pharmaceuticals, Inc.
 1,288,053 $47,799,646
7 CRNX
Crinetics Pharmaceuticals, Inc.
 1,222,080 $45,730,233
8 CYTK
Cytokinetics Inc
 457,907 $39,009,097

All Filings in REPL

Export CSV
8 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $7,259,528 655,784
2026-03-31 $12,109,850 1,582,987
2026-03-31 $765,000 100,000
2025-12-31 $12,065,649 1,241,322
2025-12-31 $243,000 25,000
2025-09-30 $4,101,565 978,894
2025-09-30 $209,500 50,000
2025-06-30 $96,616 10,400